This expression pattern was consistent with the AMPK activity (examined by IHC using anti- phospho-AMPKα (pAMPKα) on the same tissue array) with the tumor stage (data not shown), indicating that a progressive loss of AMPK-β1 expression occurs during the development and progression of ovarian cancer. Here, PRKAA2 is linked to ovarian carcinoma.